Health experts redefine cardiovascular disease risk, prevention and management

Health experts are redefining cardiovascular disease (CVD) risk, prevention and management, according to a new American Heart Association presidential advisory published today in the Association’s flagship journal Circulation.

HAEMATO AG (von GBC AG) – Biotech Investments

Original-Research: HAEMATO AG – von GBC AG Einstufung von GBC AG zu HAEMATO AG Unternehmen: HAEMATO AG ISIN: DE000A289VV1 Anlass der Studie: Research Note Empfehlung:

September 15, 2023

Novel Amyloid Drug Improves Mid-Term Outcomes in ATTR Cardiomyopathy

AMSTERDAM — Novel anti-amyloid agent acoramidis improved a composite of outcome endpoints in the pivotal ATTRibute-CM trial for transthyretin mediated amyloidosis (ATTR) cardiomyopathy, with suggestion

August 30, 2023

H1 Launches Gen AI Tool to Accelerate Clinical Trials

What You Should Know: H1, the leading source of truth for global Healthcare Professional, clinical, scientific, and research information, today announced the launch of GenosAI,

October 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.